|Print Page Close Window|
Data Suggest That Targeted Intracerebral Delivery of Brain-Derived Neurotrophic Factor Utilizing HyStem® Delivery Platform May Mitigate Ischemic Brain Injury and Restore Functional Benefits
“Results from this study, designed to simulate the clinical needs of
human stroke, underscore the ability of our proprietary HyStem® delivery
technology to target therapy dosing to a specific anatomical site such
as to the ischemic core, and minimize dissipation to surrounding
Ischemic stroke is a leading cause of death and disability, and the ischemic brain remains a difficult to reach anatomical target because of the blood-brain barrier which limits availability of systemically administered drugs. In order to reach therapeutic levels for neural repair and functional recovery, many stroke therapies would have to be administered at very high systemic doses because of the blood-brain barrier, and therefore increasing risks of systemic or off-target side effects. Implantable drug depots are being explored as a novel approach for the delivery of treatments directly to the brain. BioTime’s HyStem® technology features a unique, biocompatible hydrogel designed to provide a controlled-release drug depot and enable the effective delivery of small and large biologic molecules.
In the published study, clinicians examined the effects of BDNF, delivered via an extended release HyStem®-C hydrogel, on sensorimotor function, infarct volume, and neuroinflammation, following permanent distal middle cerebral artery occlusion (dMCAo) in rats. Improved sensorimotor function was observed in rats treated with hydrogel + BDNF(HIGH), particularly six to eight weeks following treatment implantation. Infarct volume was reduced in rats treated with hydrogel + BDNF(HIGH) as were levels of microglial, phagocyte, and astrocyte marker immunoexpression in the corpus striatum. These data suggest that targeted intracerebral delivery of BDNF using hydrogels may mitigate ischemic brain injury and restore functional deficits by reducing neuroinflammation.
HyStem® is BioTime’s cell and drug delivery platform. HyStem® technology
includes a family of unique, biocompatible hydrogels designed to
effectively deliver cells or bioactive compositions for therapeutic
benefit. HyStem® was designed to enable the effective transfer,
engraftment and metabolic support for cells. The flexible chemistry of
the HyStem® also allows for hydrogel optimization in the delivery of
drugs and therapeutics.
BioTime is a clinical-stage biotechnology company focused on the
development and commercialization of novel therapies for the treatment
of degenerative diseases. BioTime’s pipeline is based on two platform
technologies which encompass cell replacement and cell/drug delivery.
BioTime’s lead cell replacement product candidate is OpRegen®,
a retinal pigment epithelium transplant therapy in Phase 2 development
for the treatment of dry age-related macular degeneration, the leading
cause of blindness in the developed world. BioTime’s lead cell delivery
clinical program is Renevia®, an investigational medical
device being developed as an alternative for whole adipose tissue
transfer procedures. BioTime common stock is traded on the NYSE American
and TASE under the symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter,
Certain statements contained in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Any statements that are not historical fact
including, but not limited to statements that contain words such as
“will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”
should also be considered forward-looking statements. Forward-looking
statements involve risks and uncertainties. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the business of
BioTime Inc. IR
Solebury Trout IR
© Copyright BioTime, Inc.